SITE MAP | TERMS OF USE | 2013 RHYTHM PHARMACEUTICALS Press Releases Published Research back Ipsen Grants Rhythm Exclusive Worldwide License for Two Programs in the Field of Metabolic Disorders PARIS and BOSTON, March 12, 2010 Ipsen (Euronext: FR0010259150; IPN), a global biotechnology specialty...

SITE MAP | TERMS OF USE | 2013 RHYTHM PHARMACEUTICALS Press Releases Published Research back Rhythm Closes $40 Million Series A Financing Third Rock Ventures Joins Founding Investors, MPM Capital and New Enterprise Associates BOSTON, September 8, 2010 Rhythm, a biotechnology company develop...

SITE MAP | TERMS OF USE | 2013 RHYTHM PHARMACEUTICALS Press Releases Published Research back Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor BOSTON, November 27, 2012 Rhythm announced today that the company has raised an additional $8 million to complete a $3...

SITE MAP | TERMS OF USE | 2013 RHYTHM PHARMACEUTICALS Press Releases Published Research back Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study BOSTON, June 23, 2014 Rhythm announced today the presentation of results from a clinical trial that evaluated the ef...

SITE MAP | TERMS OF USE | 2013 RHYTHM PHARMACEUTICALS ABOUT RHYTHM Corporate Overview Management Board of Directors Scientific Advisory Board Investors PROGRAMS Technology: Peptide Therapeutics Focus Obesity & Diabetes GI Functional Disorders Pipeline Ghrelin: Ghrelin: Relamorelin MC4: RM-493 NE...